Donut Stress Just Test: HIV, HCV, and STI Testing and Prevention Campaign
If you are interested in participating, please email firstname.lastname@example.org.
Providers and clinical staff interested in providing treatment and care to individuals diagnosed with Hepatitis C.
- Identify best practices for opt-out HIV and HCV testing.
- Describe how a campaign can increase HIV, HCV, and STI testing rates.
- Discuss techniques used in a campaign to engage patients and clinical teams in opt-out HIV & HCV testing.
Iowa Primary Care Association
HIV, Hepatitis C (HCV), and STIs disproportionally affect the communities served by community health centers. When patients know their status, it can save lives by allowing life-saving treatment to start earlier and helps to prevent transmission to others.
The “Donut Stress Just Test” campaign was launched as part of the routine screening project by the Iowa PCA in the fall of 2021. The campaign was developed to raise awareness and promote CDC and the United States Preventive Services Task Force (USPSTF) recommendations for opt-out HIV, HCV, and STI screening at Iowa’s community health centers. Using the opt-out model, community health centers are well-positioned to reduce barriers patients may experience and promote linkage to care. It is recommended that all patients aged 13-65 are screened at least once in a lifetime for HIV. In addition to HIV, all patients between the ages of 18-79 should be screened at least once in their lifetime for HCV regardless of risk factors. It is also recommended all sexually active females under the age of 25 are screened for STIs.
Recently in Iowa, syphilis cases have significantly risen. There has been a 224% increase in early syphilis cases between 2018 to 2021. Populations that were less affected in the past are increasingly becoming affected. In many cases, signs and symptoms may not be obvious, missed, or confused with other conditions. If caught early, syphilis can be treated with a single dose of Bicillin L-A. Clinical presentation and laboratory diagnostics are essential in staging, determining treatment, and monitoring follow-up. To help in reducing these rates, it is recommended to ask several key questions to clients/patients when screening and testing for syphilis:
- Have you ever tested positive for syphilis in the past?
- When was the last time you were tested for syphilis?
- What was the result of your last syphilis test?
- Where did you get your last syphilis test (clinic/medical provider)?
- Have you had any signs or symptoms of syphilis in the past 12 months (chancres, rashes, etc.)?
- When was the last time you had sex?
- Have you had sex with anyone who has tested positive for syphilis or had signs/symptoms of syphilis?
By testing for syphilis, an early diagnosis can be made, leading to early treatment, better patient outcomes, and reduced transmission risk in our communities. Another great reason to “donut stress, just test!”
- MD: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Iowa Medical Society (IMS) through the joint providership of Des Moines University (DMU) and the Iowa Primary Care Association. DMU is accredited by IMS to provide continuing medical education for physicians. DMU designates this live, online activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
- DO: Des Moines University (DMU) is accredited by the American Osteopathic Association (AOA) to provide osteopathic continuing medical education for physicians. DMU designates this activity for a maximum of 1.5 AOA Category 2-A credits and will report CME and specialty credits commensurate with the extent of the physician’s participation in this activity.
- Nurse: Des Moines University is Iowa Board of Nursing approved provider #112. This live activity has been reviewed and approved for 1.5 continuing education contact hour(s). No partial credit awarded.
- Other Healthcare Professionals: This live activity is designated for a maximum of 1.5 AMA PRA Category 1 Credit(s)™.
No ineligible company provided financial support for this continuing education activity.
The planning committee member(s) and speaker(s) will disclose if any pharmaceuticals or medical procedures and devices discussed are investigational or unapproved for use by the U.S. Food and Drug Administration (FDA). The determination of educational content and the selection of speakers is the responsibility of the activity director.
Relevant to the content of this educational activity, the following individual(s) have no conflict(s) with ineligible companies to disclose.
- Kristi Barslou - Activity Coordinator
- Tiffany Conroy, LISM - Moderator
- Steven Donnelly, PharmD - Planning Committee Member
- Mark Hillenbrand, LISW, RSCW - Planning Committee Member
- Elizabeth Rosa - Activity Coordinator
- Megan Srinivas, MD, MPH - Planning Committee Member
- Megan Westerly, MSN, RN - Planning Committee Member
- Rebecca Clair - Speaker
Relevant to the content of this educational activity, the following individual(s) have a conflict(s) with ineligible companies to disclose. All relevant financial relationships have been mitigated.
- Douglas LaBrecque, MD - Planning Committee Member, Consultant for HepQuant
The information provided in this activity is for continuing education. It is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition. The content of each presentation does not necessarily reflect the views of Des Moines University.
- 1.50 AMA PRA Category 1 Credits™
- 1.50 AOA Category 2A
- 1.50 CE Contact Hour(s)
- 1.50 IBON